Compare · EW vs MDT
EW vs MDT
Side-by-side comparison of Edwards Lifesciences Corporation (EW) and Medtronic plc. (MDT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. EW focuses on Industrial Specialties, while MDT focuses on Biotechnology: Electromedical & Electrotherapeutic Apparatus.
- MDT is the larger of the two at $102.71B, about 2.1x EW ($48.42B).
- Over the past year, EW is up 11.7% and MDT is down 4.3% - EW leads by 16.0 points.
- MDT has been more active in the news (22 items in the past 4 weeks vs 6 for EW).
- Both have 25 recent analyst ratings on file.
- Company
- Edwards Lifesciences Corporation
- Medtronic plc.
- Price
- $83.99+0.54%
- $80.00-1.23%
- Market cap
- $48.42B
- $102.71B
- 1M return
- +3.30%
- -7.06%
- 1Y return
- +11.71%
- -4.25%
- Industry
- Industrial Specialties
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NYSE
- NYSE
- IPO
- News (4w)
- 6
- 22
- Recent ratings
- 25
- 25
Edwards Lifesciences Corporation
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral surgical valve replacement; aortic heart valves; annuloplasty rings; cardiac cannula devices; beating heart mitral valve repair system for the treatment of degenerative mitral regurgitation, as well as various procedure-enabling platforms to advance minimally invasive surgery. In addition, it offers critical care products, such as hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; pulmonary artery catheters; arterial pressure monitoring products, oximetry central venous catheters, as well as monitoring platforms that display a patient's physiological information; and Acumen Hypotension Prediction Index, which alerts clinicians in advance of a patient developing low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Medtronic plc.
Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiovascular Portfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; AF ablation products; insertable cardiac monitor systems; mechanical circulatory support; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves; percutaneous coronary intervention stents, surgical valve replacement and repair products, endovascular stent grafts, percutaneous angioplasty balloons, and products to treat superficial venous diseases in the lower extremities. The Medical Surgical Portfolio segment offers surgical products, including surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases. The Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The Diabetes Operating Unit segment offers insulin pumps and consumables, and continuous glucose monitoring systems. The company was founded in 1949 and is headquartered in Dublin, Ireland.
Latest EW
- Edwards Lifesciences to Present at the BofA Securities 2026 Health Care Conference
- Edwards Lifesciences Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Edwards Lifesciences Reports First Quarter Results
- Edwards Lifesciences to Host Earnings Conference Call on April 23, 2026
- SEC Form 4 filed by Ullem Scott B.
- SEC Form 4 filed by Lippis Daniel J.
- SEC Form 4 filed by Bobo Donald E Jr
- Edwards Lifesciences upgraded by Wolfe Research with a new price target
- Two Year Data on Edwards Lifesciences' EVOQUE System Continue to Demonstrate Significant and Sustained Patient Benefits
- Amendment: SEC Form SCHEDULE 13G/A filed by Edwards Lifesciences Corporation
Latest MDT
- FDA Grants Orchestra BioMed Additional Breakthrough Device Designation for AVIM Therapy
- Chief Accounting Officer Blomquist Denise L. was granted 1,508 units of Ordinary Shares and covered exercise/tax liability with 318 units of Ordinary Shares, increasing direct ownership by 10% to 13,262 units (SEC Form 4)
- Director Nabel Elizabeth G was granted 2,111 units of Ordinary Shares and covered exercise/tax liability with 207 units of Ordinary Shares, increasing direct ownership by 11% to 19,584 units (SEC Form 4)
- Director Powell Kendall J was granted 2,111 units of Ordinary Shares and covered exercise/tax liability with 207 units of Ordinary Shares, increasing direct ownership by 4% to 51,380 units (SEC Form 4)
- Director Lofton Kevin E was granted 2,111 units of Ordinary Shares and covered exercise/tax liability with 207 units of Ordinary Shares, increasing direct ownership by 23% to 10,140 units (SEC Form 4)
- Director Jellison William R was granted 1,444 units of Ordinary Shares, increasing direct ownership by 29% to 6,444 units (SEC Form 4)
- Director Lee Joon Sup was granted 1,803 units of Ordinary Shares (SEC Form 4)
- Director Lewis Gregory P was granted 2,111 units of Ordinary Shares and covered exercise/tax liability with 207 units of Ordinary Shares, increasing direct ownership by 49% to 5,754 units (SEC Form 4)
- Director Hogan Randall J was granted 2,111 units of Ordinary Shares and covered exercise/tax liability with 207 units of Ordinary Shares, increasing direct ownership by 4% to 48,998 units (SEC Form 4)
- Director Groetelaars John P was granted 1,444 units of Ordinary Shares (SEC Form 4)